Equity · Healthcare
NAMS
NewAmsterdam Pharma Company N.V. · NasdaqGM
The line runs $29 on 10 June through $31.67 on 17 July, on a scale from $27.5 to $37.5. Days the market did not trade hold the previous close, flat.
The chart above plots the price of NAMS over the range selected — one day to the full history — drawn by TradingView from their own data. Our own licensed end-of-day series holds 26 sessions over that window: $29 on 10 June 2026 through $31.67 on 17 July 2026.
Finazon · prior-day close · valuation computed from SEC EDGAR filings · as of Sep 8, 2026
NAMS insider trades
NAMS has no Form 4 filing in the last 90 days, so there is no summary for that window. The most recent filings we hold are below, the newest dated 15 September 2025.
Compensation mechanics Share grants, option exercises, tax withholding and transfers. They reach the same Form 4 as a trade, but they are not the insider buying or selling on the open market, so no purchase or sale value applies to them.
NAMS reported financials
NAMS reported revenue of $22.5M for the fiscal year ended 31 Dec 2025. Net income over the same period was −$203.8M.
Source: SEC EDGAR XBRL company facts · latest period ended 30 Jun 2026
NAMS earnings
no date announced in SEC filings yet
Reported figures & scheduled dates · SEC EDGAR filings
NAMS institutional holders
11 of the 45 institutional funds we track reported a NAMS position for the quarter ended 30 Jun 2026 — a combined $412.6M; the latest of those filings landed 02 Sep 2026.
Showing the 10 largest of 11 reported positions. The figures above count all of them.
Source: SEC EDGAR 13F filings
NAMS fails-to-deliver
On 11 Aug 2026, 52 shares of NAMS failed to deliver (about $1K).
Source: SEC fails-to-deliver (CNS) data